Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Primary progressive aphasia (PPA) is a rare neurological syndrome that gradually impairs a person’s language. Baycrest Canada ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...

Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in fast-growing marketsThe merger delivers on Evestia ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

A recent study found that only 15% of cancer survivors discussed trials with their healthcare providers, with ...